Whether such modulators would be directly relevant to pharmacotherapy is unclear, as the links between low GluD1 expression and schizophrenia and GluD2 overactivity and cerebellar ataxia may pertain to early development (51, –53) and thus be inaccessible to pharmacotherapy. The gene discussed is GLUD1; the disease is aceruloplasminemia.